|
Cannapharmarx Inc
CPMD's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cannapharmarx Inc 's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.74 %
Cannapharmarx Inc net loss deacreased by in III. Quarter 2023 year on year, Cannapharmarx Inc net loss increased by -57.03 % in III. Quarter 2023 year on year,
• More on CPMD's Growth
|
|
Cannapharmarx Inc current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.
Cannapharmarx Inc PEG ratio is at -0.01
|
Company |
|
PE TTM
|
Industry |
2020.53 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.
• More on CPMD's Valuation
|
|
|
|
|
Cannapharmarx Inc current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.
Cannapharmarx Inc PEG ratio is at -0.01
|
Company |
|
PE TTM
|
Industry |
2020.53 |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.
| | | |